An embodiment of the present invention provides an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, including:

an ephedra powder agent of which ephedrine content is concentrated to be 3.0 to 4.0%, which is greater than 0.5 to 2.5% when it is in a natural state, and of which the ephedrine content is maintained constant at 3.0 to 4.0%; and a side-effect-preventing powder agent for each constitution prescribed based on Sasang constitutional medicine in order to prevent a side effect of the ephedra powder agent, wherein a weight ratio of the ephedra powder agent and the side-effect-preventing powder agent is 8-10:1 to 9-11:1.

Provided is a homogeneous polysaccharide ESP-B4, method for producing the same and use thereof. The ESP-B4 is a polysaccharide monomer, which is isolated from the traditional Chinese medicine Ephedra sinica Stapf, Ephedra intermedia Schrenk et C. A. Mey, or Ephedra equisetina Bge. HPSEC-ELSD shows a single symmetrical peak. The chemical construction of ESP-B4 is an acidic heterosaccharide. It is composed of xylose, arabinose, glucose, rhamnose, mannose, galactose, glucuronic acid and galacturonic acid with a molar ratio of 1.0:4.5:1.0:2.0:5.5:1.5:50. The molecular weight of ESP-B4 is 2.3710.sup.7 Da, and the content of galacturonic acid was 75.2%. The application of ESP-B4 is significant activity against infectious acute lung injury, respiratory distress syndrome, asthma, pneumonia, trachea and bronchitis. Therefore, it can be used for severe infectious acute lung injury caused by SARS virus, influenza a virus, avian influenza virus. Meanwhile, ESP-B4 has few side effects, simple preparation method, and it is suitable for industrial production.

Provided is a homogeneous polysaccharide ESP-B4, method for producing the same and use thereof. The ESP-B4 is a polysaccharide monomer, which is isolated from the traditional Chinese medicine Ephedra sinica Stapf, Ephedra intermedia Schrenk et C. A. Mey, or Ephedra equisetina Bge. HPSEC-ELSD shows a single symmetrical peak. The chemical construction of ESP-B4 is an acidic heterosaccharide. It is composed of xylose, arabinose, glucose, rhamnose, mannose, galactose, glucuronic acid and galacturonic acid with a molar ratio of 1.0:4.5:1.0:2.0:5.5:1.5:50. The molecular weight of ESP-B4 is 2.3710.sup.7 Da, and the content of galacturonic acid was 75.2%. The application of ESP-B4 is significant activity against infectious acute lung injury, respiratory distress syndrome, asthma, pneumonia, trachea and bronchitis. Therefore, it can be used for severe infectious acute lung injury caused by SARS virus, influenza a virus, avian influenza virus. Meanwhile, ESP-B4 has few side effects, simple preparation method, and it is suitable for industrial production.

The invention relates to plant extracts for stimulating the synthesis of hyaluronan synthase, particularly the synthesis of hyaluronan synthase 2 (HAS2). Specific aims of the invention are to increase firmness and/or elasticity and/or tissue moisturization, and/or increase the skin barrier effect, and/or increase tissue resilience, and/or modulate angiogenesis, or the neocreation of blood capillaries, and/or improve healing, and/or cell proliferation, migration or differentiation, and/or skin atrophy, and/or intended to combat the effects of ageing on the skin, and in particular to combat the loss of firmness of the skin observed in the course of ageing, and/or atrophied scars.

The invention relates to plant extracts for stimulating the synthesis of hyaluronan synthase, particularly the synthesis of hyaluronan synthase 2 (HAS2). Specific aims of the invention are to increase firmness and/or elasticity and/or tissue moisturization, and/or increase the skin barrier effect, and/or increase tissue resilience, and/or modulate angiogenesis, or the neocreation of blood capillaries, and/or improve healing, and/or cell proliferation, migration or differentiation, and/or skin atrophy, and/or intended to combat the effects of ageing on the skin, and in particular to combat the loss of firmness of the skin observed in the course of ageing, and/or atrophied scars.

The invention relates to plant extracts for stimulating the synthesis of hyaluronan synthase, particularly the synthesis of hyaluronan synthase 2 (HAS2). Specific aims of the invention are to increase firmness and/or elasticity and/or tissue moisturization, and/or increase the skin barrier effect, and/or increase tissue resilience, and/or modulate angiogenesis, or the neocreation of blood capillaries, and/or improve healing, and/or cell proliferation, migration or differentiation, and/or skin atrophy, and/or intended to combat the effects of ageing on the skin, and in particular to combat the loss of firmness of the skin observed in the course of ageing, and/or atrophied scars.

This cellulose powder has: an average degree of polymerization of 100 to 350; a weight average particle size of over 30 m, but less than 250 m; an apparent specific volume of 2 to less than 15 cm.sup.3/g; and an organic carbon content from residual impurities, which is defined by the total organic carbon content (%) during 1% NaOH extraction to the total organic carbon content (%) during pure water extraction, of over 0.07 to 0.3%.

This cellulose powder has: an average degree of polymerization of 100 to 350; a weight average particle size of over 30 m, but less than 250 m; an apparent specific volume of 2 to less than 15 cm.sup.3/g; and an organic carbon content from residual impurities, which is defined by the total organic carbon content (%) during 1% NaOH extraction to the total organic carbon content (%) during pure water extraction, of over 0.07 to 0.3%.

Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.

Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.